Company
Atalanta Therapeutics
Pioneering treatments for CNS diseases
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Atalanta Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Atalanta was created to address the urgent global need for interventions to treat neurological diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.
Funding snapshot
- Total raised
- $97MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $97M2025-01-28
Funding rounds
- Series B
- $97M2025-01-28, Company stated
Loading relationship preview